Anti-CD20 (rituximab) treatment improves atopic eczema

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 1, 2008, Pages 122-128

  Simon, Dagmar ^a   Hösli, Susanne ^a   Kostylina, Ganna ^a   Yawalkar, Nikhil ^a   Simon, Hans Uwe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atopic dermatitis; B cells; biologics; cytokines; inflammation; rituximab; T cells

Indexed keywords

ALLERGEN; CD20 ANTIBODY; CLEMASTINE; CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 15; PARACETAMOL; RITUXIMAB;

ACANTHOSIS; ADULT; ARTICLE; ATOPIC DERMATITIS; B LYMPHOCYTE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HISTOLOGY; HUMAN; INFLAMMATORY CELL; LYMPHOCYTE DEPLETION; MALE; MONITORING; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; SKIN; SKIN INFILTRATE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 38149055540     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.11.016     Document Type: Article

References (49)

1. Novak N., Bieber T., and Leung D.Y.M. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 112 (2003) S128-S139
2. Akdis C.A., Akdis M., Simon D., Dibbert B., Weber M., Gratzl S., et al. T cells and T cell-derived cytokines as pathogenic factors in the non-allergic form of atopic dermatitis. J Invest Dermatol 113 (1999) 628-634
3. Lugovic L., Lipozenocic J., and Jakic-Razumovic J. Atopic dermatitis: immunophenotyping of inflammatory cells in skin lesions. Int J Dermatol 40 (2001) 489-494
4. Simon D., Vassina E., Yousefi S., Kozlowski E., Braathen L., and Simon H.U. Reduced dermal infiltration of cytokine-expressing cells in atopic dermatitis following short-term topical tacrolimus treatment. J Allergy Clin Immunol 114 (2004) 887-895
5. Simon D., Vassina E., Yousefi S., Braathen L.R., and Simon H.U. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60 (2005) 944-951
6. Schmid-Grendelmeier P., Simon D., Simon H.U., Akdis C.A., and Wüthrich B. Epidemiology, clinical features, and immunology of the intrinsic (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 56 (2001) 841-849
7. Bruynzeel-Koomen C., van Wichen D.F., Toonstra J., Berrens L., and Bruynzeel P.L. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 278 (1986) 199-205
8. Grillo-Lopez A.J., White C.A., Varns C., Shen D., Wei A., McClure A., et al. Overview of the clinical development of rituximab: first monoclonal antibody for the treatment of lymphoma. Semin Oncol 26 (1999) 66-73
9. Jezirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
10. Cancro M.P., Allman D.M., Hayes C.E., Lentz V.M., Fields R.G., Sah A.P., et al. B cell maturation and the selection at the marrow-periphery interface. Immunol Res 17 (1998) 3-11
11. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenic role of B cells. Arthritis Rheum 46 (2002) 2029-2033
12. Leandro M.J., Edwards J.C.W., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
13. Edwards J.C.W., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
14. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
15. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
16. Dupuy A., Viguier M., Bedane C., Cordoliani F., Blaise S., Aucouturier F., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140 (2004) 91-96
17. Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 51 (2004) 817-819
18. Arin M.J., Engert A., Krieg T., and Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153 (2005) 620-625
19. Ahmed A.R., Spigelman Z., Cavacini L.A., and Rosner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355 (2006) 1772-1779
20. Joly P., D'Incan M., and Musette P. Rituximab for pemphigus vulgaris. N Engl J Med 356 (2007) 521-522
21. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 48 (2003) 1484-1492
22. Hanifin J.M., and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venerol (Stockh) 92 (1980) S44-S47
23. Hanifin J.M., Thurston M., Omoto M., Cherill R., Tofte S.J., and Graeber M. The eczema area and severity index (EASI): assessment of reliability an atopic dermatitis. Exp Dermatol 10 (2001) 11-18
24. Simon H.U., Plötz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
25. Simon H.U., Seelbach H., Ehmann R., and Schmitz M. Clinical and immunological effects of low dose IFN-α treatment in patients with corticosteroid-resistant asthma. Allergy 58 (2003) 1250-1255
26. Simon D., Braathen L.R., and Simon H.U. Increased lipopolysaccharide-induced TNF-α, IFN-γ, and IL-10 production in atopic dermatitis. Br J Dermatol 157 (2007) 583-586
27. Simon D., Borelli S., Braathen L.R., and Simon H.U. Peripheral blood mononuclear cells from extrinsic and intrinsic atopic dermatitis patients demonstrate increased capacity of generating interleukin-13 but differ in their potential of synthesising interferon-γ. Allergy 57 (2002) 431-435
28. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 18 (2002) 3-7
29. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (Duluth) 25 (2001) 402-408
30. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nature Immunol 2 (2001) 764-766
31. Silverman G.J. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci 12 (2007) 2194-2206
32. Stockinger B., Zal T., Zal A., and Gray D. B cells solicit their own help from T cells. J Exp Med 183 (1996) 891-899
33. Macaulay A.E., DeKruyff R.H., Goodnow C.C., and Umetsu D.T. Antigen-specific B cells preferentially induce CD4+ T cells to produce IL-4. J Immunol 158 (1997) 4171-4179
34. Clark R., and Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol 125 (2005) 629-637
35. Jirapongsananuruk O., Hofer M.F., Trumble A.E., Norris D.A., and Leung D.Y. Enhanced expression of B7.2 (CD86) in patients with atopic dermatitis: a potential role in the modulation of IgE synthesis. J Immunol 160 (1998) 4622-4627
36. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cells depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
37. Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., and Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167 (2001) 4710-4718
38. Lin L., Nonoyama A., Oshiba A., Kabasawa Y., and Mizutani S. TARC and MDC are produced by CD40 activated human B cells and are elevated in the sera of infantile atopic dermatitis patients. J Med Dent Sci 50 (2003) 27-33
39. Frezzolini A., Paradisi M., Zaffiro A., Provini A., Cadoni S., Ruffelli M., et al. Circulating interleukin 16 (IL-16) in children with atopic eczema/dermatitis syndrome (AEDS): a novel serological marker of disease activity. Allergy 57 (2002) 815-820
40. Masuda K., Katoh N., Okuda F., and Kishimoto S. Increased levels of serum interleukin 16 in adult type atopic dermatitis. Acta Derm Venereol 83 (2003) 249-253
41. Kaser A., Dunzendorfer S., Offner F.A., Ludwiczek O., Enrich B., Koch R.O., et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol 165 (2000) 2474-2480
42. Harada H., Kawano M.M., Huang N., Harada Y., Iwato K., Tanabe O., et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81 (1993) 2658-2663
43. Manz R.A., Thiel A., and Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 388 (1997) 133-134
44. Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48 (2003) 2146-2154
45. Vallerskog T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., Van Vollenhoven R., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122 (2007) 62-74
46. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20. What do B cells do?. Clin Immunol 117 (2005) 207-213
47. Cooper H.L., Healy E., Theaker J.M., and Friedmann P.S. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 28 (2003) 366-368
48. Sfikakis P.P., Boletis J.N., and Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17 (2005) 550-557
49. Levesque M.C., and St. Clair E.W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 121 (2008) 13-21